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Introduction
Abdominoperineal resection (APR) is the standard surgery 
for locally advanced rectal cancer located within 5  cm of 
the anal verge [1]. With tumor involvement of the base or 
trigone of the bladder and prostate, total pelvic exentera-
tion (TPE) may be required to achieve negative margins 
[2]. These patients often require double stomas: one for 
urinary diversion, such as an ileal conduit; and another for 
fecal diversion, such as a sigmoid colostomy. However, 
this procedure compromises quality of life severely. Recent 
advances in sphincter-preserving operations (SPOs) includ-
ing intersphincteric resection (ISR) and Ultra-low anterior 
resection (U-LAR) for very low rectal cancer have allowed 
Coloanal Anastomosis (CAA) or coloanal canal anasto-
mosis to be performed without adverse effects on outcome 
[3–9]. Neobladder construction has also become a standard 
procedure following cystoprostatectomy for invasive blad-
der cancer [10, 11]. Conversely, en bloc radical prostatec-
tomy is an option for selected patients who would otherwise 
need TPE for locally advanced rectal cancer involving the 
prostate [12–15]. Bladder-preserving surgery with cysto-
urethral anastomosis (CUA) allows for voiding via the ure-
thra with urinary continence. Collectively, these advances 
may improve post operative quality of life for patients with 
locally advanced rectal cancer requiring TPE by enabling 
surgery to be performed without a stoma or with only a sin-
gle stoma [16–20]. We have explored these approaches in 
patients with locally advanced primary or recurrent rectal 
cancer at our institute since 2001. As leakage from a CUA 
is a concern associated with this surgery, we conducted a 
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Purpose Sphincter-preserving operations performed with 
bladder-preserving surgery and a cystourethral anastomosis 
(CUA) do not require a urinary stoma, but leakage from the 
CUA may develop. The aim of this study was to evaluate 
the efficacy of performing an additional flap operation.
Methods The subjects were 39 patients who under-
went bladder-preserving surgery for advanced rectal can-
cer involving the prostate, between 2001 and 2015.32 of 
whom had a CUA and one of whom had a neobladder. Five 
of these 32 patients underwent an ileal flap operation, 2 
underwent an omental flap operation, and 3 underwent an 
operation using both flaps.
Results Leakage developed in 3 (30%) of the 10 patients 
who underwent additional flap operations, but in 14 
(60.9%) of the 23 patients who did not undergo a flap oper-
ation. The mean periods of catheterization for the patients 
who suffered leakage were 31 weeks (8–108 weeks) in 
those without a flap and 16 weeks (8–20 weeks) in those 
with a flap. Four (33.3%) of the 12 patients with leakage 
after surgery without a flap had a period of urinary cath-
eterization >30 weeks, and 2 (16.7%) had leakage of 
CTCAE grade 3. There were no cases of leakage after flap 
surgery.
Conclusion An additional flap operation may decrease 
the risk of leakage from a CUA.
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prospective study to evaluate the effectiveness of additional 
flap surgery for reducing this leakage in bladder-preserving 
surgery for locally advanced primary rectal cancer.
Methods
Patients
Between January, 2001 and January, 2015, 39 patients with 
locally advanced primary and recurrent rectal cancer with 
clinical involvement of the prostate underwent extended 
colorectal resection, combined with radical prostatectomy, 
at the National Cancer Center Hospital East. All 39 patients 
were originally considered to be candidates for TPE or ISR 
with radical cystoprostatectomy. However, ultimately, the 
urinary bladder was preserved in 38 patients and a neo-
bladder was reconstructed in one patient, to avoid TPE and 
radical cystoprostatectomy. Four patients agreed to undergo 
preoperative radiochemotherapy based on our previous pro-
tocol [6], although this is not standard protocol for resect-
able rectal cancer in Japan. The rectal tumor was staged 
using the 7th UICC TNM staging system.
Table  1 lists the age, tumor grade, and clinical tumor 
stage of the 39 patients. Four of the patients had cT1b-3 
tumors with synchronous primary prostatic cancer and as 
all these patients underwent CUA, they were included in 
the study. The mean age was 63 years (range 26–76 years) 
and the mean distance from the tumor to anal verge was 
3.5  cm (range 0–6.5  cm). To measure the distance from 
the rectal tumor to the anal verge, rigid proctoscopy with 
measurement and/or digital examination was used. Preop-
erative staging was done using a transanal digital exami-
nation, computed tomography (CT), magnetic resonance 
imaging (MRI), endoscopic ultrasonography, colonoscopy, 
and barium enema. Position emission tomography was also 
performed preoperatively to exclude widespread metastatic 
disease.
All patients had a localized rectal tumor involving the 
prostate and seminal vesicle, or combined with carcinoma 
of the prostate, without evident distant metastases preop-
eratively. All resected specimens were examined clinico-
pathologically and involvement of adjacent organs and 
surgical margins, perioperative morbidity and mortality, 
locoregional control, overall survival (OS), and disease-
free survival (DFS) were investigated. Informed consent 
was obtained from all patients and approval was given by 
the institutional review board. The study was performed 
in accordance with the Helsinki Declaration of 1975 and 
1983.
Indications and surgical procedure
Bladder-sparing extended en bloc rectal resection combined 
with radical prostatectomy was considered if the tumor was 
adhered to the prostate or bladder, or if an adequate mar-
gin between the tumor and these organs seemed impossible 
to achieve, based on magnetic resonance imaging (MRI) 
and computed tomography (CT) findings. Patients under-
going this surgical procedure had a residual urinary blad-
der with available capacity of 50 ml and the possibility for 
CUA. Distant metastasis, wide-ranging involvement of the 
urinary bladder, prostate, and marked pelvic lymph node 
metastasis were generally considered contraindications 
for this operation, since preservation of the available uri-
nary bladder was impossible in patients with wide-ranging 
involvement of the urinary bladder. Those patients under-
went TPE.
The surgical technique was as follows: after plac-
ing the patient in the lithotomy position, total mesorec-
tal excision with lateral pelvic node dissection was per-
formed (although lateral node dissection is not standard 
outside of Japan). The ureters were located and carefully 
protected throughout the procedure, and the superior ves-
ical artery was preserved bi- or unilaterally. The status of 
involvement of the rectum and base of the bladder was 
Table 1  Clinical characteristic 
of the patients
AV anal verge, P prostate, SV seminal vesicle, SU urethral sphincter muscle, B bladder, U ureter, L levator 
muscle
Primary, n = 34 Recurrence, n = 5
Mean age, years (range) 65 (43–76) 55 (43–63)
Mean distance from AV, cm (range) 3.5 (0-6.5) Unknown




Involved organs Prostate (SV,SU,B,L):18 (90%) 
SV:1 (5%)
B + U:1 (5%)
P:5 (100%)
Node involvement (clinical) cN(+):17 cN(+):0
Surg Today 
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investigated at this point. After confirming the absence of 
wide-ranging involvement of the urinary bladder, blad-
der sparing surgery was deemed possible. The rectal 
cancer, prostate, and seminal vesicles were resected en 
bloc cooperatively, by colorectal and urological surgeons 
using the usual methods for radical prostatectomy and 
ISR or APR. APR was performed when safe surgical mar-
gins could not be obtained by ISR. Frozen section exami-
nation of the resected specimen was done to confirm can-
cer-free radial and distal margins, evaluate the extent of 
pelvic invasion, and determine whether limited resection 
was possible. If tumor invasion was suspected in the sur-
gical margins on the intraoperative histological examina-
tion, the operative procedure was converted to TPE. After 
confirming preservation of the membranous urethra and 
bladder, the bladder neck was reconstructed and a CUA 
was created by urological surgeons (Fig. 1). An ileal flap, 
made using 5 cm of mucoresected ileum, was placed with 
tissue surrounding the CUA (Fig. 2). The ileal flap has a 
good blood supply, which is why it was our first choice. 
When the omentum was sufficiently long, we considered 
adding an omental flap to the ileal flap. If the sphincter 
urethra muscle was sacrificed because of probable tumor 
invasion, a cystostomy was created for voiding through 
a catheter. Finally, a CAA was created with a diverting 
stoma or permanent colostomy by colorectal surgeons. 
We resected the prostate with a sufficient margin when it 
was thought that the rectal cancer had invaded the pros-
tate before CRT. The bladder catheter was left in place 
for 2–3 weeks and removed after cystography had con-
firmed an intact anastomosis. The diverting stoma was 
closed 3 months after radical surgery.
Evaluation of CUA leakage
On postoperative day 28, the strength of the CUA was 
assessed by cystography using 100–150  ml of standard 
contrast agent (sodium amidotrizoic acid meglumine 
injection, Urografin; Bayer) diluted in 100–150  ml of 
0.9% NaCl inserted under gravity into the bladder via the 
Foley indwelling catheter. Anteroposterior and oblique 
views were obtained after contrast instillation. The cys-
tography findings were evaluated by an experienced urol-
ogist. Perianastomosis leakage was classified as no leak-
age or leakage. In a patient with no leakage, the catheter 
was removed the same day. For a patient with leakage, 
radiological follow-up was conducted after 1–3 months. 
The leakage grade was classified using the National Can-
cer Institute Common Terminology Criteria for Adverse 
Events (CTCAE; urethral anastomotic leak) [21].




Five patients (T4, N2: n = 3; T4, N1: n = 1; T4,N0: n = 1) 
between 2001 and 2010 agreed to undergo preoperative 
radiochemotherapy using our old protocol, despite this 
treatment for resectable rectal cancer not being standard 
in Japan, even for patients undergoing TPE. These patients 
received 45 Gy to the whole pelvis over a 5-week period, 
followed by resection after 2 weeks. In addition, 5-fluoro-
uracil (5-FU) was administered as a continuous infusion 
at 250  mg/m2/day during the radiotherapy to enhance the 
radiotherapeutic efficacy. Postoperative chemotherapy 
(5-FU/leucovorin therapy or FOLFOX) was offered to 
patients with pathological stage III disease.
Follow-up
The mean follow-up period was 70 months (range 0–162 
months). Examinations were performed every 3 or 4 
months for 2 years postoperatively, and every 6 months 
thereafter. These comprised clinical examinations; labo-
ratory tests including tumor marker levels; lung, liver, 
and pelvic CT; and physiological assessment using anal 
manometry and uroflowmetry.
Statistical analysis
The starting point for survival and recurrencefree inter-
vals was the day of the operation, and data ofpatients who 
were alive or free of recurrence were censored at the last 
follow-up. OS was defined as the time from radical sur-
gery until death from any cause. Local recurrence was 
defined as recurrence confined to the pelvis, and distant 
recurrence was defined as recurrence outside of the pel-
vis. Statistical analyses wereperformed using SPSS for 
Windows v. 11.0 J (SPSS Japan, Tokyo, Japan). OS and 
DFS curves were calculated using the Kaplan–Meier 
method.
Ethical conduct of the study
The present study was registered with the University Hos-
pital Medical Information Network Clinical Trials Registry 
(no. 000010530). The institutional review broad approved 
the protocol for this study. An independent safety monitor-
ing committee monitored the safety of the patients through-
out the study period. The study was performed under the 
Declaration of Helsinki and Japanese Good Clinical Prac-
tice Guidelines.





Twenty patients had localized tumors with clinical involve-
ment of the prostate, three had clinical T3 lower rectal 
tumors with synchronous primary prostate cancer, and one 
underwent radical prostatectomy. Five patients had local 
recurrence with clinical involvement of the prostate. No 
procedures were converted to TPE because of inadequate 
margins. Twenty-two patients underwent anal SPOs (ISR, 
n = 18; U-LAR, n = 4) with radical prostatectomy, and 16 
underwent APR with radical prostatectomy because the 
lower edge of the tumor was very close to the anal verge or 
the tumor involved the external anal sphincter. One patient 
underwent recurrent tumor resection and radical prostatec-
tomy after APR.
Urinary reconstruction was performed with CUA in 32 
patients, a neobladder was created in one patient, and cys-
tostomy was performed in 6 patients because of the intraop-
erative histological probability of cancerous invasion of the 
sphincter urethra muscle. Five patients underwent an ileal 
flap operation, two underwent an omental flap operation, 
and three underwent an operation using both flaps. Twenty-
two patients had no stoma, 11 had a single stoma, and 6 
had a fecal stoma and cystostomy (Tables 1, 2). The median 
operative time was 505.5  min (range 315–857  min) and 
the median intraoperative blood loss was 3002  ml (range 
225–12,531 ml).
Pathological findings
All resected margins were examined pathologically and 
confirmed to be cancer-free. The final pathological exami-
nation indicated pT4 in 16 patients (41.0%), with histologi-
cal cancerous invasion of the prostate in 11; a pT3 tumor 
with fibrosis or inflammatory changes surrounding the 
tumor in 15; and a pT2 tumor with the same histological 
changes in 4. The T1b patient, 2 of the 4 pT2 patients, and 
1 of the 15 pT3 patients had synchronous primary prostate 
cancer, and it was difficult to separate the rectal tumors 
safely from the prostate during the operation in these 
Table 2  Type of surgery and 
pathological findings
No stoma, n = 22; single stoma, n = 11; CS + stoma, n = 6
ISR intersphincteric resection, APR abdominoperineal resection, CUA cysto-urethral anastomosis, CS cys-
tostomy, CAA colo-anal anastomosis, ES external anal sphincter
*All patients underwent radical prostatectomy
Primary, n = 34 Recurrence, n = 5
Type of surgery* LAR (5.9%) LAR (40.0%)
APR (41.2%) APR (40.0%)
ISR (50.0%) Recurrence tumor resec-
tion: 1 (20.0%)
ISR + total cystectomy + neobladder: 1 
(2.9%)
Reconstruction Urinary CUA: 28 (82.3%) Urinary CUA: 4 (80.0%)
CUA with flap: 9 (26.5%) CUA with flap: 1 (20.0%)
CS: 5 (14.7%) CS: 1 (20.0%)
Neobladder: 1 (2.9%)
Fecal CAA: 18 (52.9%) Fecal DST: 2 (40.0%)
DST (5.9%) Stoma: 3 (60.0%)
Stoma: 14 (41.1%)




No tumor: 2 (5.9%)
Involved organs Prostate: 9 (26.5%) Prostate: 1 (20.0%)
Prostate + SV: 1 (2.9%) Prostate + SV: 1 (20.0%)
ES: 1 (2.9%) SV: 2 (40.0%)
Small intestine: 1 (2.9%)
Node involvement (pN) pN1: 12 (35.3%)
pN3: 6 (17.6%)
Surgical margins Negative, n = 34 (100%) Negative, n = 5 (100%)
 Surg Today
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patients. Curative resection was achieved in 38 patients by 
bladder-preserving surgery and in one patient by using a 
neobladder.
Morbidity and mortality
Table  3 summarizes the morbidity for this series. Seven 
patients had no postoperative complications. Of the 32 
patients (82.1%) who had a complication, a CUA leak was 
identified in 17 (51.5%). A colo-anal anastomotic leak 
developed in 4 of 18 patients after an ISR and a double-
stapling anastomosis leak developed in 1 of 4 patients after 
LAR. One patient with an anastomotic leak and ISR suf-
fered from colo-anal anastomotic stenosis before closure of 
the diverting ileostomy. Additional surgery for the anasto-
motic stricture was thus performed by plastic surgeons, and 
the diverting stoma was closed 14 months after the initial 
operation. Other complications included pelvic abscess 
(10.3%, 4/39), wound infection (10.3%, 4/39), and bowel 
obstruction (17.9%, 7/39). There was no mortality in hospi-
tal or within 30 days postoperatively.
Leakage from the CUA
A CUA leak was identified in 17 patients and required 
catheterization through the anastomosis site for 8 to 108 
weeks postoperatively. Of the 10 patients who had addi-
tional flap operations, 3 (30.0%) suffered leakage, whereas 
of the 23 patients who had no flap operation, 14 (60.9%) 
suffered leakage (Table  3). Two patients with ileal flaps 
and one with ileal and omental flaps suffered CUA leakage. 
The mean periods of catheterization in the patients with 
leakage were 31 weeks (8–108 weeks) for those without a 
flap and 16 weeks (8–20 weeks) for those with a flap. The 
period of urinary catheterization was more than 30 weeks 
in 4 of the 14 patients with leakage after surgery without 
a flap (33.3%; 2 patients without IF: periods of catheteri-
zation unknown), but in none of those with leakage after 
flap surgery (Table  4). Twelve patients with no flap and 
three patients with an additional flap had CTCAE grade 2 
leakage. Two patients with no flap had grade 3 leakage and 
required reoperation using a gracilis muscle flap, whereas 
none of those with leakage after additional flap surgery 
required reoperation.
Survival
By the last follow-up, in January 2013, 28 patients were 
alive and 11 had died. The causes of death included mul-
tiple bone metastases (n = 1), multiple lung metastases 
(n = 4), multiple liver and bone metastases (n = 1), multiple 
lung and bone metastases (n = 1), and local re-recurrence 
(n = 2). The patient treated with a neobladder died of an 
abdominal injury sustained in a fall (Table  5). The esti-
mated 5-year OS and DFS rates were 68.6 and 51.0% for 
patients with primary disease and 40.0 and 20.0% for those 
with recurrence, respectively.
Local and overall recurrence
Recurrence developed in 15 (44.1%) of the 34 patients with 
primary disease, and the incidence of local recurrence was 
26.7% (Table 5). Local recurrences developed in the presa-
cral area in two patients, in the perianastomotic site of the 
CUA in one, and in the left obturator internus muscle in 
one. One patient with recurrence in the presacral area and 
one with recurrence in the perianastomotic site of the CUA 
underwent tumor resection with sufficient surgical margins. 
The other patient with recurrence in the presacral area had 
simultaneous lung metastasis and received chemotherapy. 
The patient with recurrence in the left obturator internus 
muscle received chemoradiotherapy and complete remis-
sion was achieved (Table  5). This patient and the patient 
with recurrence in the preanastomotic site had no evidence 
of disease after resection of the local recurrence.
Table 3  Postoperative complications anastomotic leakage
SPO sphincter-preserving operation, CUA cysto-urethral anastomosis, 
CAA colo-anal anastomosis
Anastomotic leakage SPO with CUA: 11/22 (50.0%)
APR with CUA: 6/11 (54.5%)
CUA leakage with flap: 3/10 (30.0%)
CUA leakage with no flap 14/23 (60.9%)
CAA: 4/18 (22.2%), DST:1/4 (25.0%)
Pelvic abscess 4/39 (10.3%)
Wound infection 4/39 (10.3%)
Ileus 7/39 (17.9%)
Overall morbidity 32/39 (82.1%)
Mortality 0/39 (0%)
Table 4  Duration of 
catheterization in the 
cystourethral anastomosis 
leakage group
Two patients without a flap had unknown periods of catheterization




More than 30 weeks with 
catheterization (n)
CTCAE Grade3 (n)
Without IF 12 31 (8–108) 4 (33.3%) 2 (16.7%)




Orthotopic neobladder surgery is often used as an alterna-
tive for patients undergoing radical cystectoprostatectomy 
for bladder cancer to enable voiding via the urethra with 
urinary continence [16, 17]. Patients undergoing radical 
prostatectomy with CUA for carcinoma of the prostate can 
also void with continence via the urethra. SPOs for lower 
rectal cancer have become more common with improved 
surgical techniques such as ISR, which was devised in the 
1980s, and further concepts established in the 1990s.
ISR is a procedure that gives sufficient surgical mar-
gins by removing part or all of the internal anal sphinc-
ter and restoring bowel continuity for patients with rectal 
cancer located within 5  cm of the anal verge. Fixation of 
the lower urinary tract organs, such as the prostate, in pri-
mary locally advanced rectal cancer is not uncommon in 
men. Standard therapy for such patients in the absence of 
extra-pelvic metastases has been total pelvic exenteration to 
ensure negative surgical margins. However, this procedure 
requires urinary and fecal diversion through the formation 
of double stomas. In 1966, separate prostatectomy was sug-
gested as a routine additional procedure to prevent void-
ing problems after APR for rectal cancer. Three cases of 
patients with synchronous rectal and prostate cancer, who 
underwent separate dissections were reported recently [12]. 
Another report described combined radical retropubic pros-
tatectomy and proctosigmoidectomy en bloc in 11 selected 
patients with cancer limited to the prostate [13–15, 18].
We believe that even more limited excision is feasible 
and preferable if the tumor can be removed en bloc. Pres-
ervation of the prostate may also be possible if significant 
tumor shrinkage can be achieved by neoadjuvant therapy 
such as preoperative chemoradiation or chemotherapy. 
However, preoperative chemoradiotherapy for advanced 
rectal cancer is not a standard option in Japan, even for 
patients undergoing TPE, and it may also cause postopera-
tive complications. Since 2001, we have used a combined 
approach for primary or recurrent rectal cancer involv-
ing lower urinary tract organs or with synchronous pros-
tatic cancer. In our series of 39 patients treated during this 
period, the bladder was preserved in 38 patients to avoid 
TPE, and anal SPOs using ISR techniques were performed 
whenever possible. Cancer-free margins were obtained in 
all patients.
Similar procedures without ISR were first described by 
Campbell et  al. [13] in a report of two patients in whom 
en bloc excision yielded negative surgical margins. Wiig 
et al. [18] found no local recurrence in follow-up for 10–50 
months after en bloc radical prostatectomy for 6 patients 
with locally advanced or recurrent rectal cancer involving 
the prostate, with 4 of 5 patients with a CUA having a good 
quality of life and none wanting an ileal conduit.
There have been a few reports on these operations of 
bladder preservation, but the complication rate of leakage 
from the CUA was relatively high. In the present series, 
anastomotic urethral leak developed in 17 (53.1%) of 32 
patients with a CUA. Similarly, Wiig et al. [18] found that 3 
(50%) of 6 patients with a CUA had an anastomotic urethral 
leak with one major leakage. The frequency of anastomotic 
leaks was significantly higher in patients undergoing APR 
with a CUA. In contrast, the urethral anastomotic leakage 
rate was lower in patients undergoing ISR or ultra-LAR 
with a CUA, as the neorectum is located behind the CUA. 
In studies of the leakage rate from a CUA in patients under-
going radical retropubic prostatectomy only [22, 23], extra-
version was not found in 135 (75%) of 179 cystograms, and 
the clinically prolonged leakage rate was 0.6% (11/1796). 
All these patients had the rectum behind the CUA. Ure-
thral anastomotic leaks are thus probably due to a lack of 
Table 5  Patients with recurrence and re-recurrence
ANED alive with no evidence of disease, AWD alive with disease
Primary, n = 15 Recurrence, n = 5
Lung 3
Liver 5 1 (liver resection → ANED)
Bone 1
Lung + bone 1
Local 1 (paraanastomotic site tumor resection → ANED) 2 (death, Local resection → death)
Liver + lung + local 2 (liver resection → lung and local → chemotherapy → death, liver resec-
tion → lung resection → left obturator internus muscle recurrence → 
Cape + RT → CR → ANED)
Liver + bone 1
Lung + local 1 (lung → chemotherapy → local resection → death)
Lymph 1 (chemotherapy → ANED)
Liver + abdominal wall 1 (local resection → ANED)
 Surg Today
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supporting tissue behind the anastomosis after removal of 
the rectum in patients who have undergone APR. An addi-
tional flap operation may decrease leakage from a CUA and 
reduce the duration of urinary catheterization for a patient 
with leakage. By performing this new ileal flap operation 
we improved the leakage rate to 30.0% (3/10) from 60.7% 
(14/23). Four of the 16 patients with leakage after sur-
gery without a flap (33.3%) required urinary catheteriza-
tion for more than 30 weeks, whereas none of the patients 
with leakage after flap surgery required prolonged urinary 
catheterization. This demonstrates the effectiveness of 
this method and how it improves quality of life. Measures 
to prevent urethral anastomotic leakage using a flap of the 
greater omentum behind the anastomosis or an additional 
ileal flap, such as a gracilis flap, thus appear warranted.
The method described in this study is a part of an opera-
tion for cancer; therefore, prognosis and recurrence are 
very important considerations. Similar procedures were 
described by Campbell et al. [13] in two patients who had 
no evidence of local recurrence at their 1-year follow-up. 
Wiig et al. [18] also found no local recurrence during fol-
low-up for 10 to 50 months after en bloc radical prostatec-
tomy in 6 patients with locally advanced or recurrent rectal 
cancer involving the prostate. However, as there were few 
cases of long-term follow-up included in these reports [13, 
18], the long-term outcomes of the procedures are unclear.
In the present study, six patients (15.3%) suffered local 
recurrence during follow-up, including one recurrence in 
the presacral area. This local recurrence was unlikely to 
have been prevented had the patient undergone TPE. The 
patient underwent successful resection of the recurrent 
tumor, but died of multiple lung metastases 86 months 
after the initial operation. In another patient, local recur-
rence developed at the paravesical site. This patient also 
underwent resection of the recurrent tumor and remains 
re-recurrence free after 90 months. In a third patient, local 
recurrence developed at the parasacral site. Resection of 
the recurrent tumor was not possible and despite chemo-
therapy, the patient died 38 months after the first operation. 
In a fourth patient, local recurrence developed in the left 
internal obturator muscle. Again, tumor resection was not 
possible, but chemoradiotherapy was given and this lesion 
is in complete remission, with the patient being re-recur-
rence free after 60 months. The last two patients both had 
recurrent lesions in the pelvic area at their first operation 
in our hospital. One underwent resection of the recurrent 
tumor, but died 55 months after the operation; and for the 
other patient, resection of the recurrent tumor was not pos-
sible and he died 1 month after the operation.
In 2013, Yang et  al. published a systematic review 
on pelvic exenteration for rectal cancer [24]. The 5-year 
survival rate for patients with primary advanced rectal 
cancer ranged from 31 to 77% (median, 52%) [25–40] 
in 17 studies reviewed, whereas that for patients with 
locally recurrent rectal cancer ranged from 0 to 37% 
(median, 18%) in 13 studies reviewed [25, 27, 30, 31, 
34–36, 38–43]. Moreover, the 5-year disease-free sur-
vival rate was 52 and 13% for those with primary vs. 
recurrent tumors, respectively [34]. In the current study, 
acceptable 5-year OS and DFS rates of 68.8 and 51.1%, 
respectively, were achieved for patients undergoing sur-
gery for primary locally advanced very low-lying rec-
tal cancer, with a mean follow-up of 70 months (range 
0–162 months). For those with recurrence, the 5-year OS 
was 40.0% and the 5-year DFS was 20.2%. Despite our 
concerns about the risk of local recurrence after limited 
excision to preserve the urinary bladder, the local recur-
rence rate in this series was relatively low. A remaining 
problem is prevention of distant metastases, but to date, 
the procedures reported here appear to be oncologically 
safe for selected patients with rectal cancer involving the 
prostate.
Patients with a CUA also reported satisfactory con-
trol of voiding function, with a voiding style resembling 
that of patients with an ileal neobladder. Unfortunately, 
six patients required cystostomy because the sphincter 
urethra muscle was sacrificed due to probable cancerous 
invasion. These patients voided via an inserted catheter 
that was exchanged once a month, much like those with 
an ileal conduit. An obvious difference between neoblad-
der and bladder-sparing surgery is that the neobladder is 
made using intestine, which results in inevitable long-
term complications such as mucus production, nutritional 
abnormalities, metabolic acidosis, skeletal demineraliza-
tion, and a risk of malignant transformation in the intes-
tinal segment [44, 45]. No such problems are associated 
with bladder-sparing surgery.
In conclusion, this prospective study demonstrates the 
effectiveness of the ileal flap method for reducing CUA 
leakage and improving quality of life. Our results suggest 
that this new method should be evaluated using a similar 
trial design for patients with advanced rectal patients, to 
avoid colostomy.
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